Text Size

Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients

Holló G., Hommer A., Antón López A., Ropo A.


  • 2014
  • Journal of Ocular Pharmacology and Therapeutics
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, Semmelweis University, Maria St. 39, Budapest 1085, Hungary; Krankenanstalt Sanatorium Hera, Vienna, Austria; Department of Glaucoma, Institut Catala de Retina-Inici, Barcelona, Spain; Santen Oy, Clinical Research and Medical Affairs, Helsinki, Finland

Related Publications

An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.


Relaxation of Precontracted Ciliary Artery and Ciliary Muscle In Vitro by Kinin Peptides: Relevance to Retinal Blood Flow and Intraocular Pressure Regulation

Sharif N.A., Kulkarni-Chitnis M., Okolie A., Chaudhry S.D., Njie-Mbye Y.F., Ohia S.E.


The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys

Maki K., Kimura E., Yamamoto Y., Fuwa M., Toris C.B., Fan S., Shimazaki A., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022